Zanoni, Lucia http://orcid.org/0000-0002-6784-8220
Bianchi, Lorenzo
Nanni, Cristina
Pultrone, Cristian
Giunchi, Francesca
Bossert, Irene
Matti, Antonella
Schiavina, Riccardo
Fiorentino, Michelangelo
Romagnoli, Daniele
Fonti, Cristina
Lodi, Filippo
D’Errico, Antonietta
Brunocilla, Eugenio
Porreca, Angelo
Fanti, Stefano
Funding for this research was provided by:
Regione Emilia-Romagna (PRUA1GR-2013-00000171 (Programma di Ricerca Regione- Università Area 1 Bando Giovani Ricercatori “Alessandro Liberati” 2013”))
Article History
Received: 18 December 2020
Accepted: 24 May 2021
First Online: 2 July 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Local Bioethics Committee (EudraCT number 2014–003165-15; Local Ethical Committee code: 139/2014/O/Sper).
: All patients included in the study signed informed consent to participate and publication. Informed consent to participate and for publication was obtained from all individual participants included in the study.
: Lucia Zanoni had a scientific-only relationship with the company “Blue Earth Diagnostics Ltd.” as Medical Staff of the Sponsored Study BED001 (118/2014/O/Oss) (no financial relationship, no compensation received). She was Principal Investigator of the project entitled “18F-FACBC PET/CT for staging high risk prostate cancer” funded by “Programma di ricercar Regione-Università 2013-Area 1 “Ricerca Innovativa,” Bando “Alessandro Liberati-Giovani Ricercatori.” In the context of this project, Lucia Zanoni received a granted 1-year SSN contract as nuclear medicine project manager (both scientific and financial relationship; 2016). Cristina Nanni provided consultancy for Blue Earth Diagnostics Ltd. 2018–1019. She was Principal Investigator of the project entitled ANTI-3-18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) in comparison to [<sup>11</sup>C]choline PET/CT in the evaluation of patients with prostate cancer radically treated and with rising PSA, “Programma di ricerca Regione-Università 2010–2012-Area 1” “Ricerca Innovativa,” Bando “Alessandro Liberati-Giovani Ricercatori.” Irene Bossert, Cristina Fonti, Cristian Pultrone, and Francesca Giunchi received granted universitary contracts as Staff of the project entitled “18F-FACBC PET/CT for staging high risk prostate cancer” funded by “Programma di ricerca Regione-Università 2013-Area 1” “Ricerca Innovativa,” Bando “Alessandro Liberati-Giovani Ricercatori.” Stefano Fanti, with respect to the mentioned paper, declares that he attended an advisory board of Blue Earth Diagnostics in 2014 and in 2015. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.